GlassScriptPhysician profile
Catherine N Roush
NPI 1033269014
$4,137.97
in general payments reported to CMS, 2019-2025
45 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $338 · 2021: $696 · 2022: $986 · 2023: $584 · 2024: $771 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.25 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.15 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $382.35 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $291.39 | 2019-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Mayne Pharma Commercial LLC | $251.44 | 2021-2024 | |
| Coloplast Corp | $234.49 | 2021-2025 | |
| Daiichi Sankyo INC. | $161.57 | 2019-2023 | Injectafer |
| Coopersurgical, INC. | $151.48 | 2019-2023 | Paragard T 380a, Mara Console |
| Therapeuticsmd, INC. | $146.23 | 2019-2022 | |
| Gynesonics, INC. | $137.16 | 2022 | |
| Organon LLC | $135.20 | 2022-2024 | Nexplanon |
| Pfizer INC. | $124.62 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.93 | 2019-2025 | |
| Evofem Biosciences, INC. | $108.72 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $93.71 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $91.62 | 2021-2025 | Zurzuvae |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $79.74 | 2022-2023 | Tymlos |
| Vertical Pharmaceuticals, LLC | $71.78 | 2019 | |
| Millicent US INC | $57.64 | 2024 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $57.16 | 2019-2025 | Gardasil 9 |
| Ethicon US, LLC | $56.10 | 2022-2025 | Vistaseal |
| Amgen INC. | $53.10 | 2020-2024 | Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $51.87 | 2021 | |
| Avion Pharmaceuticals | $51.74 | 2019-2023 | Balcoltra |
| Allergan, INC. | $49.89 | 2019-2020 | |
| Agile Therapeutics, INC. | $45.36 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $44.78 | 2020-2023 | Slynd |
| Dysis Medical, INC. | $44.71 | 2020 | |
| Channel Medsystems, INC. | $37.45 | 2023-2025 | |
| Boston Scientific Corporation | $34.06 | 2021-2023 | |
| Covidien LP | $29.05 | 2019 | |
| Baxter Healthcare | $28.15 | 2023 | Tisseel |
| Smith+Nephew, INC. | $27.03 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $26.88 | 2020-2022 | |
| Lupin INC. | $25.55 | 2020 | |
| Monaghan Medical Corporation | $25.08 | 2024 | Aeroeclipse |
| Neuronetics, INC. | $24.63 | 2024 | Neurostar Tms Therapy System |
| Northgate Technologies, INC. | $18.46 | 2024 | Stimsite |
| Ascend Therapeutics US, LLC | $17.85 | 2022 | |
| Aspira Women'S Health INC | $17.77 | 2021 | |
| Medicem INC. | $17.11 | 2021 | |
| Roche Diagnostics Corporation | $16.99 | 2021 | |
| Meditrina | $16.89 | 2023 | |
| Currax Pharmaceuticals LLC | $15.93 | 2024 | Contrave |
| Shield Therapeutics INC | $14.32 | 2023 | Accrufer |
| Vyne Pharmaceuticals INC. | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Roush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.